Combination Therapy with Liposomal Amphotericin B Plus Anidulafungin in Invasive Aspergillosis
Combination therapy with liposomal amphotericin B plus anidulafungin is NOT routinely recommended as primary therapy for invasive aspergillosis, but may be considered in select patients with severe, refractory, or high-risk disease. Voriconazole remains the primary recommended agent, with liposomal amphotericin B or isavuconazole as alternatives 1, 2.
Primary Therapy Recommendations
The evidence consistently shows that primary combination therapy lacks sufficient clinical data to support routine use 1, 3. The 2016 IDSA guidelines explicitly state that "primary combination therapy is not routinely recommended based on lack of clinical data" 2. However, combination therapy may be considered in individual patients with documented invasive pulmonary aspergillosis 2.
When to Consider Combination Therapy
Combination therapy with voriconazole plus an echinocandin (including anidulafungin) may be considered in:
- Patients on immunosuppressants 4
- High-risk patients with severe disease 4
- Salvage therapy situations 3
- Refractory disease or treatment failures 3
Important caveat: The 2023 COVID-19 associated aspergillosis guidelines noted that higher mortality was observed in patients receiving combination therapy compared to monotherapy/sequential monotherapy, though this may reflect selection bias toward treating sicker patients 4.
Dosing Regimen
If combination therapy is pursued:
Liposomal Amphotericin B (AmBisome)
- Dose: 3-5 mg/kg IV daily 3
- Infusion: Over approximately 120 minutes (can reduce to 60 minutes if well-tolerated) 5
- Reconstitution: Use only Sterile Water for Injection (12 mL per 50 mg vial = 4 mg/mL concentration) 5
- DO NOT use saline for reconstitution or mix with other drugs 5
Anidulafungin
- Loading dose: 200 mg IV on day 1 3
- Maintenance: 100 mg IV daily 3
- No dose adjustment needed when co-administered with liposomal amphotericin B 6
Critical drug interaction note: The FDA label confirms no significant pharmacokinetic interaction between anidulafungin and liposomal amphotericin B, requiring no dose adjustments 6.
Monitoring Requirements
Clinical Monitoring
- Serial clinical evaluation of all symptoms and signs
- CT imaging at regular intervals (frequency individualized based on disease acuity and rapidity of infiltrate evolution) 1
- Expect potential increase in pulmonary infiltrate volume during first 7-10 days, especially with granulocyte recovery 1
Laboratory Monitoring
- Serum galactomannan assays: Serial monitoring is promising but remains investigational 1
- Progressive increase in galactomannan levels = poor prognosis
- Resolution to normal levels alone is NOT sufficient to discontinue therapy 1
- Renal function: Critical for liposomal amphotericin B (nephrotoxicity risk, though lower than conventional amphotericin B) 1
- Hepatic function: Monitor transaminases 6
- Electrolytes: Particularly potassium, magnesium, calcium 6
Therapeutic Drug Monitoring
- Consider for azoles if used sequentially after combination therapy 3
- Review potential drug interactions 3
Duration of Therapy
Minimum 6-12 weeks of treatment 3, 2, with duration varying based on:
- Site of disease
- Degree and duration of immunosuppression 2
- Evidence of disease improvement (clinical and radiographic) 4, 3
- Resolution or stabilization of all clinical and radiographic manifestations 7
Treatment should NOT be discontinued prematurely based solely on galactomannan normalization 1.
Sequential vs. Concomitant Approach
The evidence suggests sequential therapy may be preferable to concomitant combination:
- Animal studies show liposomal amphotericin B followed by echinocandin was as effective as liposomal amphotericin B alone 8
- Greater decrease in fungal burden with liposomal amphotericin B supports using it prior to echinocandin 8
- Sequential monotherapy is an accepted approach 4
Alternative Preferred Regimens
Before resorting to combination therapy, consider these evidence-based alternatives:
First-Line Monotherapy (Strongest Evidence)
- Voriconazole: 6 mg/kg IV q12h × 2 doses, then 4 mg/kg IV q12h 1, 3, 2 - Strong recommendation, high-quality evidence
- Isavuconazole: 200 mg IV q8h × 6 doses, then 200 mg IV daily 4, 2 - Recent network meta-analysis suggests optimal efficacy-safety balance 9
- Liposomal amphotericin B: 3-5 mg/kg IV daily 1, 3, 2 - Strong recommendation, moderate-quality evidence
Critical Pitfalls to Avoid
- Do NOT use echinocandins as primary monotherapy for invasive aspergillosis 3, 2 - they are effective only in salvage therapy or combination regimens
- Do NOT reconstitute liposomal amphotericin B with saline - causes precipitation 5
- Do NOT discontinue therapy based solely on galactomannan normalization 1
- Do NOT delay surgical intervention when indicated (lesions near great vessels, chest wall invasion, persistent hemoptysis) 3
- Reduce immunosuppression when feasible - critical for favorable outcomes 7, 2
Adjunctive Measures
- Surgical debridement: Consider for accessible localized disease, sinonasal involvement, or high-risk pulmonary lesions 3, 2
- Immunosuppression reduction: When feasible, strongly recommended 2
- Secondary prophylaxis: Required for patients needing subsequent immunosuppression after successful treatment 3, 2